Gieschke R, Cluydts R, Dingemanse J, De Roeck J, De Cock W
Department of Clinical Pharmacology, F. Hoffmann-La Roche, Basel, Switzerland.
Methods Find Exp Clin Pharmacol. 1994 Nov;16(9):667-75.
The effects of bretazenil 0.25 and 0.5 mg, a partial agonist at the benzodiazepine receptor, on sleep electroencephalogram (EEG), subjective sleep quality and morning psychomotor performance were compared to zolpidem 10 mg and placebo using noise as an experimental sleep disturbing factor in a single dose, double-blind, crossover study. Twelve healthy volunteers were subjected to prerecorded traffic noise with a mean sound level of 52 dB(A) during eight hours in bed. Significant effects of noise were found on sleep electroencephalogram (EEG) parameters (rapid eye movement [REM] sleep, stage 2 sleep and number of arousals), and subjective sleep quality assessments, but not on psychomotor performance (choice reaction time, digit span memory, and symbol digit substitution). Both drugs reduced the number of shifts between sleep stages and the number of arousals and increased REM sleep latency. Only after 0.5 mg bretazenil, stage 2 sleep increased and REM sleep decreased. Both doses of bretazenil significantly affected performance in the symbol digit substitution test. Sleep quality improved under drug treatments compared to placebo. The results suggest that experimental sleep disturbance can be a valuable tool in the investigation of potential sleep promoting compounds.
在一项单剂量、双盲、交叉研究中，以噪声作为实验性睡眠干扰因素，将苯二氮䓬受体部分激动剂0.25毫克和0.5毫克的布瑞氮卓对睡眠脑电图（EEG）、主观睡眠质量和早晨精神运动表现的影响与10毫克唑吡坦和安慰剂进行了比较。12名健康志愿者在床上8小时期间暴露于平均声级为52分贝（A）的预先录制的交通噪声中。发现噪声对睡眠脑电图（EEG）参数（快速眼动[REM]睡眠、2期睡眠和觉醒次数）以及主观睡眠质量评估有显著影响，但对精神运动表现（选择反应时间、数字广度记忆和符号数字替换）没有影响。两种药物都减少了睡眠阶段之间的转换次数和觉醒次数，并增加了REM睡眠潜伏期。仅在服用0.5毫克布瑞氮卓后，2期睡眠增加而REM睡眠减少。两种剂量的布瑞氮卓在符号数字替换测试中均显著影响表现。与安慰剂相比，药物治疗改善了睡眠质量。结果表明，实验性睡眠干扰可能是研究潜在促睡眠化合物的一种有价值的工具。
